Glioblastoma, the most common form of brain cancer is a deadly disease for which at present there is no cure. Now, researchers have published research results that show how repurposing the old drug flavopiridol could be an effective strategy to cut short sugar availability and impair cancer growth.
A new study produced by an interdisciplinary team led by Prof. Antonio Giordano, director of the Sbarro Institute for Cancer Research and Molecular Medicine at Temple University, tracks the development process and efficacy of the Italian translation of the Derriford Appearance Scale 24 (DAS24), an important clinical tool in identifying quality-of-life issues for breast cancer patients, especially concerns regarding body shame, depression, anxiety, overall appearance and appearance identity.
More than 30 prominent international scientists gathered to discuss the state-of-the-art, as well as promising future approaches for the treatment of lung cancer at the stunning 17th century Borgo San Luigi, in Monteriggion (Siena)i, in the heart of the Tuscany countryside.
In a study published in the International Journal of Cancer, researchers focused on the role of metabolic factors such as fasting glucose and body mass index (BMI), to determine their correlation to tumor stage at diagnosis. Results indicate an association between these metabolic measures and ovarian cancer which the authors believe worthy of further investigation.
A study published in the international journal, Cancer Biology and Therapy, describes research into the correlation between generalized obesity and treatment outcomes in breast cancer patients younger than 45 years old.
The recent publication of the manuscript entitled “Body mass index and treatment outcomes in metastatic breast cancer patients treated with Eribulin”, which has just appeared in the “Journal of Cellular Physiology”, has newly brought metastatic breast cancer to the attention of our cancer research community.
The Sbarro Health Research Organization, Inc. (SHRO), in collaboration with the National Italian American Foundation (NIAF), Temple University’s College of Science and Technology and the Giovan Giacomo Giordano Foundation, will organize the Medical Conference “Health and Research: Beyond the Eyes” that will be held in Exhibition Hall C of the Washington Marriot Wardman Park Hotel in Washington, DC on Saturday, October 17th, 2015 at 9:00 am.
A review article published on the journal Oncotarget focusing on RB role in apoptosis provides a comprehensive overview on the role of RB proteins in the coordinated control of cell decisions.
Researchers have uncovered a new molecular mechanism - a function of the NONO protein - whereby cells protect their genome from the detrimental effect of UV radiation and govern DNA replication in cellular mitosis. A recent study investigates what happens when this molecular mechanism malfunctions.
Researchers from the lab of Antonio Giordano, MD, PhD, Director and Founder of the Sbarro Institute for Cancer Research and Molecular Medicine at Temple University in Philadelphia, PA (www.shro.org), have uncovered a new molecular mechanism whereby human cells protect their genome from the detrimental effect of UV radiations.
Once more, the multifactorial and heterogeneous nature of breast cancer fascinates researchers and is newly confirmed and re-interpreted in light of the results of a study entitled “Metformin and breast cancer: basic Knowledge in clinical context” published in April 2015 in the international journal Cancer Treatment Reviews.
Once more, the multifactorial and heterogeneous nature of breast cancer fascinate researchers and is newly confirmed by the results of a study entitled “Anthropometric, metabolic and molecular determinants of human epidermal growth factor receptor 2 expression in luminal b breast cancer”, published in December 2014 in the international journal Journal of Cell Physiology.
A new molecular alteration, consisting in the subcellular delocalization of the well known tumor suppressor protein pRb2/p130, has been recently identified, adding up a new component in the complex molecular portrait that characterizes gastric cancer.
he Sbarro Health Research Organization, Inc. (SHRO), in collaboration with the National Italian American Foundation (NIAF), Temple University's College of Science and Technology and the Giovan Giacomo Giordano Foundation, will organize the medical conference "Bioinnovation: towards new treatment of disease in Biopharma and Academia" that will be held in the Jay Room of the Washington Hilton Hotel in Washington, DC. on October 25th 2014 from 2:00 to 4:00PM .
Research in breast cancer has lately allowed to characterize molecular features that have increasingly become the targets for novel therapeutic interventions. Trastuzumab has revolutionized the treatment of patients with HER2 positive breast cancer. At the same time, we have gained knowledge on the importance of glucose metabolism in several tumours, including breast cancer
a new study from the Sbarro Health Research Organization and the University of L’Aquila (Italy) has investigated the role of 4-HNE and PPAR β/δ during AD progression and in physiological aging.
Mesothelioma is a very aggressive cancer associated with asbestos exposure, which is usually diagnosed in an advanced stage. So far no therapeutic strategy has proven effective against this deadly cancer and the prognosis remains very poor with only few exceptions.
Philadelphia, 17.11.13: The Sbarro Health Research Organization, the College of Science and Technology of Temple University, Integrated Systems Engineering (ISENET) and ISENET-USA LLC teamed up to organize a Tissue Microarray (TMA) Workshop on the value of the TMA technology in biomarker validation, drug response and diagnostics on November 20th, 2013, at University City Science Center, 3711 Market Street, Philadelphia PA.
The Sbarro Health Research Organization, Inc. (SHRO), in collaboration with the National Italian American Foundation (NIAF), Temple University's College of Science and Technology and the Giovan Giacomo Giordano Foundation (http://www.shro.org/SHRO/IggGiordano.html) , will host the "Conference on Current Advances in Medicine, Surgery and Biotechnology" on October 26, 2013 at 3:00-5:00PM in the Independence Room of the Washington Hilton Hotel in Washington, DC.
A new study on cancer mortality in the metropolitan area of Naples and Caserta, Southern Italy, has been published in the scientific journal Cancer Biology &Therapy.
A new published study in Journal of Cellular Physiology by a team led by Dr. Antonio Giordano and Dr. Gianfranco Bellipanni of Sbarro Institute for Cancer Research and Molecular Medicine and Temple University (Philadelphia, USA) adds a new prospective on the research on pain perception.
In this study, the researchers focused on breast cancer, the most commonly diagnosed cancer and the second leading cause of cancer death in women from Western countries.
Can an avatar in a virtual environment contribute to weight loss in the real world? “Virtual reality is a powerful computer simulation of real situations in which the user interact as avatar and it can be used as support for a weight loss program” said Dr. Antonio Giordano and Dr. Giuseppe Russo of Sbarro Institute for Cancer Research and Molecular Medicine (Philadelphia, PA), in a study just published in Journal of Diabetes Science and Technology.
The Sbarro Health Research Organization congratulates Senator Ignazio R. Marino on his recent winning of the mayoral race for the Italian Capital, Rome.
On 30 and 31 May it was held in the beautiful framework of Badia, Cava de 'Tirreni, at The Hotel Scapolatiello, the VII National Conference of ASME (Mediterranean Association of Senology) entitled "Breast cancer: state of the art". The event gathered together 130 breast cancer experts from various Italian regions who confronted on multiple themes of breast cancer research.
The “Stem Cell Research Italy” Association (www.stemcellitaly.org) and the “Sbarro Health Research Organization” (www.shro.org) make a public plea for a correct use of stem cell therapy in Italy and Europe.
Epidemiological studies have indicated that dietary habits and antioxidants from diet can influence the incidence of neurodegenerative disorders such as Alzheimer's and Parkinson's diseases.
The link between obesity and cancer seems now well established although the molecular mechanisms underlying this connection are still largely unexplored. A group of researchers in Italy led by Antonio Giordano, M.D., Ph.D., the Founder and Director of the Sbarro Institute for Cancer Research and Molecular Medicine, and Center of Biotechnology, College of Science and Technology of the Temple University in Philadelphia, has studied the correlation between breast cancer and insulin resistance — an obesity-related condition in which certain cells fail to respond to the glucose-lowering action of the insulin hormone. Their findings appear in the Journal of Experimental and Clinical Cancer Research.
A new study on the incidence of breast cancer in Italy.
A recent study led by Andrew Puca, Ph.D. under the supervision and direction of Antonio Giordano, M.D., Ph.D. set out to illustrate novel mechanical transduction properties of Hematopoietic Stem Cells in relation to defining the expression of humoral factors by facilitating paracrine/autocrine signalling via microgravity.
Inactivation of the retinoblastoma tumor suppressor protein (pRb) by phosphorylation triggers uncontrolled cell proliferation. Accordingly, activation of cyclin-dependent kinase (CDK)/cyclin complexes or downregulation of CDK inhibitors appears as a common event in human cancer. Now, a new study from the Sbarro Health Research Organization shows that Pin1 (protein interacting with NIMA (never in mitosis) A-), a peptidylprolyl isomerase involved in the control of protein phosphorylation, is an essential mediator for inactivation of the pRB.
Although endocrine therapy for breast cancer has shown excellent results in controlling the disease, responsiveness to the therapy depends on whether or not there is expression of estrogen receptors in breast cancer cells. Research from the Sbarro Institute for Cancer Research and Molecular Medicine, a nonprofit cancer, cardiovascular and diabetes research center located in Philadelphia, PA, reports on the effectiveness of a new molecule, Scriptaid that restores receptivity to endocrine therapy in breast cancer cell lines that had tested negative for the expression of estrogen receptors. The findings are reported in the Journal of Cellular Physiology.
Researchers from the Sbarro Institute for Cancer Research and Molecular Medicine and the Human Health Foundation report that in a multidisciplinary study of 420 non-diabetic, breast and metastatic colorectal cancer patients treated with targeted agents, lower levels of pretreatment fasting glucose were predictive of longer times to disease progression. Such evidence was particularly significant in breast cancer patients, according to results published in the Annals of Oncology.
A compound that mimics the effects of adiponectin, a beneficial protein that is produced by fat tissue in healthy weight individuals and may exhibit protective effects against cancer, cardiovascular disease, inflammatory conditions and insulin resistance has been developed by an international consortium.
An analysis of the high incidence of the H1N1 swine-origin influenza virus (S-OIV) in 2009 in the Campania region of Southern Italy presents important findings that provide a “significant pattern for emerging viral agents at risk in global health approaches to early diagnosis and prompt therapy,” according to an article in the Journal of Cellular Physiology.
Researchers from the lab of Antonio Giordano, M.D., Ph.D., the Founder and Director of the Sbarro Institute for Cancer Research and Molecular Medicine, have identified new potential anti-tumor agents that might be effective in treating mesothelioma, one of the deadliest cancer tumors.
Scientific evidence is mounting in support of a significant increase in cancer mortality and malformations occurring in specific areas of the Campania Region of Southern Italy, where improper waste management and illegal waste trafficking have been repeatedly documented, according to “Wasting lives: the effects of toxic waste exposure on health. The case of Campania, Southern Italy” published in Cancer Biology & Therapy.
A new study from the Sbarro Health Research Organization Center for Biotechnology reveals new molecular insights into the understanding and treatment of Burkitt`s lymphoma, one of the most aggressive tumors affecting humans.
A new study uncovers mechanisms that control Rb2/p130 gene expression in lung cancer and reveals why the gene is expressed differently in small and non-small lung cancer cells.
Metabolic syndrome, associated with the sedentary lifestyle and energy dense diet of Western industrialized societies, may be an indicator of breast cancer risk in post-menopausal women, according to a new study to be released at the National Italian American Foundation event, “Let’s Talk About It: A Spotlight on Women’s Health” on October 22nd at the Washington Hilton in Washington, D.C.
While researchers have known that obesity increases the risk for the development of colon cancer, the underlying molecular mechanisms have remained unclear. Now, for the first time, a collaborative study of researchers at the Sbarro Institute for Cancer Research and Molecular Medicine at Temple University’s College of Science and Technology and the Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy have found that an increase in leptin, a cytokine that is normally increased in obese or overweight individuals, may promote colorectal neoplasms by activating colorectal cancer stem cells.
The Human Health Foundation (HHF), a nonprofit organization founded in 2006 to develop and fund biomedical research in Italy, will open its first bioscience laboratory for the investigation of breast, brain and lung cancer on June 7th in Terni, Italy.
Src (short for sarcoma) is a family of proto-oncogenic tyrosine kinases active in many cancer tumors, including medulloblastoma, the most common malignant cancer in children. A recent study shows that pyrazolo-[3,4-d]–pyrimidine-derivatives, designed to target Src, may be effective in interfering with the cell cycle and causing cancer cell death in medulloblastoma.
Researchers working at the Sbarro Institute for Cancer Research and Molecular Medicine at Temple University in Philadelphia, PA and at the University of Siena in Siena, Italy, have shed light on the possible role of inactivation of the 16INK4A gene in the progression of retinoblastoma.
Researchers from the Sbarro Institute for Molecular Medicine and Cancer Research at Temple University in Philadelphia and the Human Health Foundation in Spoleto, Italy, have found that MECP2, a gene that modifies the chromatin in the cell, has an important role in stem cell aging.
The Sbarro Health Research Organization (SHRO), a nonprofit research facility located at Temple University, will dedicate a new state-of-the-art biotechnology research center on Tuesday, October 27th, at 2 p.m. SHRO is one of the top three international laboratories, based on number of publications as ranked by the Cell Cycle Registry,
The Sbarro Health Research Organization at Temple University has launched the Columbus Cancer Foundation, a nonprofit organization that will raise funds for joint American and European educational initiatives, basic and clinical cancer research and international scientific collaboration.
The Sbarro Health Research Organization, a nonprofit center for cancer, cardiovascular and diabetes research located at Temple University in Philadelphia and the University of Siena, Italy, has launched Sponsor-A-Scientist, an innovative program that allows interested individuals to bid on e-Bay for a named fellowship to support a talented young scientist for one academic year.
A featured article in the July 2009 online issue of Nature Reviews/Drug Discovery that explores the prospects and progress of synthetic inhibitors to target cell cycle kinases in cancer forecasts that "novel compounds with increased potency, improved kinase specificity and favorable drug like properties will soon be available for clinical evaluation."
A new analysis of the incidence of breast cancer in Italy per 100,000 women between the ages of 0 to 84 from 2000 to 2005 shows a 72 percent spike above official estimates issued by the Ministry of Health, with the sharpest uptick of +28.6 percent found in the youngest group studied (ages 25 to 44).
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right